AVITA

LOE Approaching

tretinoin

NDATOPICALGEL
Approved
Jan 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

(RAR) nuclear receptors (RARα, RARβ, and RARγ) which may act to modify gene expression, subsequent protein synthesis, and epithelial cell growth and differentiation, it has not been established whether the clinical effects of tretinoin are mediated through activation of retinoic acid receptors…

Clinical Trials (5)

NCT07341659N/AActive Not Recruiting

Efficacy of Cosmetic Product RV3278B-OS0386 in the Maintenance Phase After Oral Isotretinoin Treatment of Adults Subjects With Facial Acne.

Started Feb 2025
102 enrolled
Acne
NCT04353180Phase 3Unknown

Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)

Started Aug 2021
100,000 enrolled
COVID19
NCT04690348Phase 2Recruiting

Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

Started Dec 2020
NCT03584516Phase 2/3Terminated

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Started Jan 2019
155 enrolled
Chronic Graft-versus-host Disease
NCT03320642Phase 1Terminated

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Started Feb 2018
84 enrolled
Hematologic Malignancies
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers